The A-share market witnessed a remarkable rally in healthcare and biotech sectors today, with stocks like Acumen Pharmaceutical and United Imaging Healthcare leading the charge. Against a backdrop of broader market volatility, these segments defied the trend, drawing significant investor attention and triggering double-digit gains across the board. This surge isn’t isolated—it reflects deeper, structural shifts within China’s pharmaceutical industry, fueled by policy support, innovation milestones, and growing global recognition. Here’s a breakdown of what’s driving this momentum and why it matters for investors. Policy Tailwinds Fueling the Rally Recent regulatory developments have created a favorable environment for healthcare and biotech companies. During the 2025 National Drug Safety Publicity Week, National Medical Products Administration (NMPA) Deputy Director Xu Jinghe (徐景和) highlighted China’s rising prominence in global biopharma, noting that the country now ranks second in market size and accounts for nearly 30% of the world’s innovative drug pipeline. Accelerated Approvals and Strategic Support The ’14th Five-Year Plan’ period saw the approval of 210 innovative drugs and 269 innovative medical devices, with growth accelerating in 2025. From January to July 2025 alone, 50 innovative drugs and 49 devices were approved. These figures underscore regulators’ commitment to fast-tracking breakthroughs, reducing approval times, and encouraging R&D investment. Additionally, the State-Owned Assets Supervision and Administration Commission (SASAC) hosted a biotech industry workshop in late August, where Vice Chair Tan Zuojun (谭作钧) emphasized the need to build a ‘national team’ in biopharma. This signals stronger government backing for state-owned enterprises (SOEs) to lead innovation, expand globally, and drive sectoral upgrades. Overseas Expansion and Licensing Deals A key driver of the rally is the surge in outbound licensing deals. In the first half of 2025, Chinese biopharma firms secured nearly $66 billion in overseas partnerships, reflecting growing international confidence in China’s innovation capabilities. Companies like Fosun Pharma and Harbour BioMed are striking deals with global players, enabling them to monetize pipelines and expand market reach. Case Studies: Success Stories – Fosun Pharma’s collaboration with European and U.S. firms for COVID-19 treatments and cancer therapies. – Harbour BioMed’s antibody licensing agreements with multinational pharma giants. – BeiGene’s FDA approvals and commercial partnerships in North America. These deals not only generate revenue but also validate the quality and competitiveness of homegrown innovations. Collective Procurement Reforms Easing Pressures China’s volume-based procurement (VBP) program, once a headwind for drugmakers, is evolving. Recent optimizations have reduced price-cutting pressures, particularly for high-value consumables and innovative products. Companies like MicroPort and Mindray have seen earnings stabilize as VBP impacts diminish, allowing them to refocus on higher-margin segments. Analyst Perspectives on VBP Citic Securities notes that医疗器械板块 (medical device sector) companies are leveraging China’s engineering talent and supply chain advantages to drive incremental innovation. Zhongtai Securities adds that as VBP overhangs clear, the sector is poised for a cyclical rebound, with Q3 2025 likely marking an inflection point. Institutional and Retail Investor Sentiment The rally has been amplified by bullish analyst reports and institutional buying. Firms like China International Capital Corporation Limited (中金公司) and Essence Securities have upgraded ratings on CXO (contract research, development, and manufacturing organizations) and device stocks, citing undervaluation and recovery potential. Key Recommendations from Brokers – Open Source Securities: Focus on CXO firms with low valuations, high overseas exposure, and exposure to trending areas like weight-loss drugs and ADC (antibody-drug conjugate) therapies. – CITIC Securities: Highlight CDMO (contract development and manufacturing organization) players benefiting from global outsourcing trends. – Everbright Securities: Advocate investing in SOEs like Sinopharm Group, which trade at discounts but are poised for value revaluation. Sector Performance Highlights Today’s top gainers included Acumen Pharmaceutical (20% limit-up), United Imaging Healthcare (+13%), and MicroPort Scientific (+10%). In the innovative drug space, Jumin Health and Tibet Rhodiola Pharmaceutical hit limit-ups, while Fosun Pharma and Humanwell Healthcare rose over 6%. Even Hong Kong-listed biotech stocks joined the rally, reflecting cross-border optimism. Notable Performers – Device Makers: Mindray, United Imaging, and Edan Instruments led the charge, with gains ranging from 4% to 20%. – Biopharma: Fosun Pharma, Harbour BioMed, and Asymchem Laboratories saw sustained buying interest. – CXOs: Wuxi AppTec and Pharmaron logged solid gains amid expectations of order and earnings recovery. Investment Implications and Strategies For investors, this rally offers both opportunities and risks. While policy support and global deals are bullish, sectors remain sensitive to regulatory changes and macroeconomic conditions. Diversification across sub-sectors—devices, drugs, CXOs—can mitigate risks. Actionable Tips – Monitor policy announcements from NMPA and SASAC for further catalysts. – Track global licensing deals and FDA approvals for Chinese companies. – Consider ETFs focused on healthcare and biotech for diversified exposure. Looking Ahead: Sustained Growth or Short-Term Spike? The convergence of policy support, innovation, and global integration suggests this rally may have staying power. As Chinese firms continue to advance in high-value areas like CAR-T therapy, ADCs, and surgical robotics, sectoral growth could accelerate. However, investors should remain cautious about volatility and regulatory tweaks. In summary, the surge in A-share healthcare and biotech stocks is underpinned by tangible fundamentals: pro-innovation policies, successful globalization, and improved procurement dynamics. For those looking to capitalize, focus on companies with robust pipelines, overseas traction, and competitive moats. Stay informed, stay diversified, and consider consulting a financial advisor to align investments with your risk tolerance and goals.
Why Are A-Share Healthcare and Biotech Stocks Surging? Key Drivers and Investment Insights
